Nymox的立场是,澄清问题仍需在后续会议上解决,并涉及一些重大的不一致之处。...查看全文
耐莫斯制药(NYMX)2023-06-30 04:35
$耐莫斯制药(NYMX)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-001155 Act: 34 Size: 10 KB 网页链接查看全文
耐莫斯制药(NYMX)2023-06-30 05:25
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-001158 Act: 34 Size: 10 KB 网页链接查看全文
耐莫斯制药(NYMX)2023-07-06 18:05
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-001216 Act: 34 Size: 27 KB 网页链接查看全文
耐莫斯制药(NYMX)2023-06-28 05:25
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-001135 Act: 34 Size: 9 KB 网页链接查看全文
耐莫斯制药(NYMX)2023-06-26 22:35
$耐莫斯制药(NYMX)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001729637-23-000006 Size: 6 KB 网页链接查看全文
耐莫斯制药(NYMX)2023-05-19 04:15
$耐莫斯制药(NYMX)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001729637-23-000003 Size: 4 KB 网页链接查看全文
耐莫斯制药(NYMX)2023-05-15 17:07
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-000844 Act: 34 Size: 1 MB 网页链接查看全文
耐莫斯制药(NYMX)2023-05-13 04:57
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-000844 Act: 34 Size: 1 MB 网页链接查看全文
耐莫斯制药(NYMX)2023-05-02 20:36
$耐莫斯制药(NYMX)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001640334-23-000736 Act: 34 Size: 5 MB 网页链接查看全文
chuminhua2022-05-25 15:30
5月24日,Nymox Pharmaceutical 宣布,FDA 就 fexapotide triflutate 用于治疗男性良性前列腺增生症 (BPH) 的上市申请发出了拒绝信(RTF)。消息传出,该公司股价暴跌 64%。
FDA 在信中引用了长期安全数据的“突出问题”。然而,Nymox 声称,在 3 月份提交申请之前,该机构在其任何一次交流中...查看全文
产业链观察2022-05-24 18:03
药闻▶2022年5月23日,$耐莫斯制药(NYMX)$ 今天报告说,它已于美国东部时间5月20日星期五下午2:48收到FDA关于公司的Fexapotide Triflutate新药申请("NDA")的拒绝提交("RTF")信。
Nymox的立场是,澄清问题仍需在后续会议上解决,并涉及一些重大的不一致之处。...查看全文
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-001216 Act: 34 Size: 27 KB 网页链接
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-001158 Act: 34 Size: 10 KB 网页链接
$耐莫斯制药(NYMX)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-001155 Act: 34 Size: 10 KB 网页链接
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-001135 Act: 34 Size: 9 KB 网页链接
$耐莫斯制药(NYMX)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001729637-23-000006 Size: 6 KB 网页链接
$耐莫斯制药(NYMX)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001729637-23-000003 Size: 4 KB 网页链接
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-000844 Act: 34 Size: 1 MB 网页链接
$耐莫斯制药(NYMX)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001640334-23-000844 Act: 34 Size: 1 MB 网页链接
$耐莫斯制药(NYMX)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001640334-23-000736 Act: 34 Size: 5 MB 网页链接
$耐莫斯制药(NYMX)$ NT 20-F Notification of inability to timely file Form 20-F Accession Number: 0001640334-23-000534 Act: 34 Size: 35 KB 网页链接